Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gb Sciences Inc (OP: GBLX )

0.0055 -0.0007 (-11.29%)
Streaming Delayed Price Updated: 9:30 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 334
Open 0.0055
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0062
Today's Range 0.0055 - 0.0055
52wk Range 0.0050 - 0.0200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R)
Via ACCESSWIRE
Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge
Via ACCESSWIRE

Performance

YTD
-14.06%
-14.06%
1 Month
-8.33%
-8.33%
3 Month
-9.84%
-9.84%
6 Month
-28.57%
-28.57%
1 Year
-68.57%
-68.57%

More News

Read More
GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
Via ACCESSWIRE
Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform
Via ACCESSWIRE
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Via Newswire.com
Topics Death
Exposures COVID-19 Death
Marijuana And Chronic Pain: Gb Sciences' Nanoparticle Technology Boosts Efficacy Of Cannabis Terpenes
Via Benzinga
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
From Gb Sciences
Via GlobeNewswire
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
Via Newswire.com
Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
From Gb Sciences
Via GlobeNewswire
Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study
Via Benzinga
Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients
Via Newswire.com
Topics Cannabis
Exposures Cannabis
Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
Via Newswire.com
TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference
Via Newswire.com
Topics Cannabis
Exposures Cannabis
New Study Shows Promising Results In Treatment Of Parkinson's Disease With Cannabinoids
Via Benzinga
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
Via Newswire.com
Topics Cannabis
Exposures Cannabis
TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article
Via Newswire.com
Topics Cannabis
Exposures Cannabis
TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property Product Safety
TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property
TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference
Via Newswire.com
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
Via Newswire.com
Exposures COVID-19
Gb Sciences To Begin Dosage Study For Cannabinoid-Containing Drug For Treatment Of Parkinson's Disease
Via Benzinga
Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge
Via Newswire.com
Topics Intellectual Property
Exposures Intellectual Property
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article
Via Newswire.com
UPDATE: Gb Sciences Issues Shareholder Letter
Via Newswire.com
Gb Sciences Issues Summary Shareholder Letter
Via Newswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.